In 2022, German scientists intravenously administered autologous CD19 CAR-T cell therapy to five patients with systemic lupus erythematosus (SLE) and demonstrated its tolerability and efficacy (Mackensen et al., 2022). This evidence concerns the gene CD19 and systemic lupus erythematosus.